Domperidone
| Domperidone | |
|---|---|
| Salts [] | |
|---|---|
| Domperidone maleate | |
| Domperidone acetate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 425.90 g/mol [1] |
| Melting point | 242.5 °C [1] |
| Solubility | 0.986 mg/L [1] |
| Predicted LogP | 3.9 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C22H24ClN5O2 |
| IUPAC name | 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one |
| SMILES | C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O |
| InChI | InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30) |
| InChIKey | FGXWKSZFVQUSTL-UHFFFAOYSA-N |
| CAS number | 57808-66-9 |
| UNII | 5587267Z69 |
| PubChem CID | 3151 |
| Pharmacokinetics[] | |
|---|---|
| Onset | 30–60 minutes[3] |
| Elimination half-life | 7–9 hours |
| Metabolism | Hepatic (CYP3A4/5) and intestinal (first-pass)[4] |
| Excretion | Feces: 66%, Urine: 32%, Breast milk: small quantities |
| Routes of administration | By mouth, rectal |
| Dosing[] |
|---|
| Oral [] | |
|---|---|
| Light | ≤ 11 mg(111x - 66.1%) |
| Common | 11 mg |
| Strong | 10 - 20 mg(56x - 33.3%) |
| Heavy | 20 mg |
| Extreme | 20 mg +(1x - 0.6%) |
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki) We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Domperidone (also known as Motilium, Domperidona, Domperidonum, Domperidon, R 33,812, Evoxin, R-33812, Kw 5338, Domilium or Apo Domperidone) is a substance of the aniline and benzimidazole class.
Chemistry
Salts []
Stereochemistry []
Domperidone is achiral.
Druglikeness
Lipinski's rule of five
Domperidone matches Lipinski's rule of five.Pharmacology
ATC Classification
- alimentary tract and metabolism (A)
- drugs for functional gastrointestinal disorders (A03)
- propulsives (A03F)
- propulsives (A03FA)
- (A03FA03)
- domperidone (A03FA03)
MeSH Classification
Mechanism of action []
Domperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting [1]
Interactions []
Medical side effects []
45 side effects listed on drug labels in SIDER 4.1 (domperidone).
- Dry mouth
- Migraine
- Palpitations
- Sudden death
- Torsade de pointes
- Abdominal pain
- Arrhythmia
- Asthenia
- Conjunctivitis
- Constipation
- Diarrhoea
- Dizziness
- Somnolence
- Dysuria
- Oedema
- Dermatitis
- Rash
- Gynaecomastia
- Headache
- Dyspepsia
- Hypotension
- Irritability
- Muscle spasms
- Lethargy
- Breast pain
- Nausea
- Nervousness
- Tension
- Pruritus
- Stomatitis
- Thirst
- Pollakiuria
- Urticaria
- Vomiting
- Menstruation irregular
- Disorientation
- Galactorrhoea
- Drug intolerance
- Dystonia
- Menopausal symptoms
- Hot flush
- Blood prolactin increased
- Insomnia
- Regurgitation
- Breast enlargement
Indications
- Abdominal bloating
- Anorexia nervosa
- Diabetic gastroparesis
- Distention
- Early satiety
- Gastric atony
- Gastritis
- Gastrointestinal symptom NOS
- Migraine
- Nausea
- Orthostatic hypotension
- Parkinson's disease
- Renal impairment
- Vomiting
Subjective effects []
| 0xea / Domperidone [] | |
|---|---|
Routes:
| |
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3151, Domperidone. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3151
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Domperidone. UNII: 5587267Z69. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/5587267Z69
Domperidone: Anti-sickness medicine used to treat nausea and vomiting. 7 January 2020. https://www.nhs.uk/medicines/domperidone/
Simard C, Michaud V, Gibbs B, Massé R, Lessard E, Turgeon J. Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 2008; 34(11–12):1013–1023. PMID 15801545. https://doi.org/10.1080/00498250400015301
Motilium product information. Health Canada. 7 January 2002. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10691
Motilium Summary of Product Characteristics (SmPC). (emc). 11 March 2024. https://www.medicines.org.uk/emc/product/4177/smpc
Motilium referral. European Medicines Agency (EMA). 31 October 2000. https://www.ema.europa.eu/en/medicines/human/referrals/motilium
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | ok | 2026-11-20 09:20:12 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 09:20:08 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 09:20:08 |
| gsrs | ok | 2026-11-20 09:20:10 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015315) | 2026-11-20 09:20:08 |
| kegg | ok | 2026-11-20 09:20:11 |
| pubchem | ok | 2026-11-20 09:20:08 |
| missing (no r/tripreports posts mention it) | 2026-11-20 09:20:08 | |
| sider | ok | 2026-11-20 09:20:08 |
| structure | ok | 2026-11-20 09:20:08 |
| wikipedia | ok | 2026-11-20 09:20:08 |